Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Media type: E-Article
Title: Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series
Contributor: Brivio, Erica; Chantrain, Christophe F.; Gruber, Tanja A.; Thano, Adriana; Rialland, Fanny; Contet, Audrey; Elitzur, Sarah; Dalla‐Pozza, Luciano; Kállay, Krisztián Miklós; Li, Chi‐kong; Kato, Motohiro; Markova, Inna; Schmiegelow, Kjeld; Bodmer, Nicole; Breese, Erin H.; Hoogendijk, Raoull; Pieters, Rob; Zwaan, Christian Michel
Published: Wiley, 2021
Published in: British Journal of Haematology
Extent: 1172-1177
Language: English
DOI: 10.1111/bjh.17333
ISSN: 0007-1048; 1365-2141
Keywords: Hematology
Abstract: <jats:title>Summary</jats:title><jats:p>No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22<jats:sup>+</jats:sup> blasts was 72% (range 40–100%, <jats:italic>n</jats:italic> = 9). The median dose in the first course was 1.74 mg/m<jats:sup>2</jats:sup> (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)‐positive patient became MRD‐negative. Six‐month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno‐occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.</jats:p>
Description: <jats:title>Summary</jats:title><jats:p>No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22<jats:sup>+</jats:sup> blasts was 72% (range 40–100%, <jats:italic>n</jats:italic> = 9). The median dose in the first course was 1.74 mg/m<jats:sup>2</jats:sup> (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)‐positive patient became MRD‐negative. Six‐month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno‐occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.</jats:p>
Footnote:

Search in field:

Recently searched for: